Zotiraciclib citrate is under clinical development by Beijing zhikangbo Medical Oncology Research and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zotiraciclib citrate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zotiraciclib citrate overview
Zotiraciclib citrate is under development for the treatment of anaplastic astrocytoma, glioblastoma multiforme (GBM), gliosarcoma, high-grade glioma and pediatric diffuse intrinsic pontine glioma (DIPG) and unspecified cancer. The drug candidate is a small molecule which is formulated as a capsule and is administered through the oral route. The drug candidate is a pyrimidine-based multi-kinase inhibitor that targets JAK2, FLT3, ERK5 (Also known as MAPK7), cyclin-dependent kinases (CDKs) 1, CDK2, CDK7 and CDK9. It was also under development for the treatment of solid tumors, relapsed chronic lymphocytic leukemia, refractory acute myeloid leukemia, lymphoma, multiple myeloma (kahler disease), acute lymphocytic leukemia (acute lymphoblastic leukemia), myelodysplastic syndrome, chronic myelocytic leukemia (chronic myeloid leukemia) and metastatic hepatocellular carcinoma.
Beijing zhikangbo Medical Oncology Research overview
Beijing zhikangbo Medical Oncology Research (Cothera Bioscience) focuses on the research and development of innovative tumor-targeted drugs. Cothera Bioscience is headquartered in Beijing, China.
For a complete picture of Zotiraciclib citrate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
